Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

medtronic plc - MDT

MDT

Close Chg Chg %
80.32 -0.14 -0.17%

Closed Market

80.18

-0.14 (0.17%)

Volume: 7.69M

Last Updated:

Jun 12, 2026, 3:59 PM EDT

Trade Now

Company Overview: medtronic plc - MDT

MDT Key Data

Open

$80.32

 Day Range

79.27 - 80.45

52 Week Range

73.32 - 106.33

 Market Cap

$103.13B

Shares Outstanding

1.28B

 Public Float

1.28B

Beta

0.60

 Rev. Per Employee

N/A

P/E Ratio

21.54

 EPS

$3.74

Yield

353.54%

 Dividend

$0.72

EX-DIVIDEND DATE

Jun 26, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

11.64M

  

MDT Performance

No Data Available

MDT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 33
Full Ratings ➔

About medtronic plc - MDT

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

MDT At a Glance

Medtronic Plc
Parkmore Business Park West
Galway, Galway 2
Phone 353-1-438-1700 Revenue 36.36B
Industry Medical Specialties Net Income 4.80B
Sector Health Technology 2026 Sales Growth 8.429%
Fiscal Year-end 04 / 2027 Employees N/A
View SEC Filings

MDT Valuation

P/E Current 21.536
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 22.338
Price to Sales Ratio 2.951
Price to Book Ratio N/A
Price to Cash Flow Ratio 14.64
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

MDT Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

MDT Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

MDT Profitability

Gross Margin 60.51
Operating Margin 20.696
Pretax Margin 16.874
Net Margin 13.20
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

MDT Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medtronic Plc - MDT

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
31.23B 32.36B 33.54B 36.36B
Sales Growth
-1.45% +3.64% +3.62% +8.43%
Cost of Goods Sold (COGS) incl D&A
12.32B 12.91B 13.49B 14.36B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.70B 2.65B 2.86B 2.96B
Depreciation
999.00M 954.00M 1.05B 1.19B
Amortization of Intangibles
1.70B 1.69B 1.81B 1.77B
COGS Growth
+4.77% +4.77% +4.46% +6.47%
Gross Income
18.90B 19.45B 20.05B 22.00B
Gross Income Growth
-5.12% +2.90% +3.07% +9.75%
Gross Profit Margin
+60.54% +60.11% +59.78% +60.51%
2023 2024 2025 2026 5-year trend
SG&A Expense
12.94B 13.36B 13.57B 14.48B
Research & Development
2.70B 2.73B 2.73B 2.87B
Other SG&A
10.24B 10.62B 10.84B 11.61B
SGA Growth
+1.24% +3.24% +1.60% +6.68%
Other Operating Expense
- 455.00M 364.00M 286.00M
Unusual Expense
729.00M 1.03B 879.00M 674.00M
EBIT after Unusual Expense
4.78B 4.70B 5.31B 6.85B
Non Operating Income/Expense
1.17B 852.00M 1.04B (2.00M)
Non-Operating Interest Income
386.00M 597.00M 511.00M 384.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
583.00M 719.00M 729.00M 715.00M
Interest Expense Growth
+5.42% +23.33% +1.39% -1.92%
Gross Interest Expense
583.00M 719.00M 729.00M 715.00M
Interest Capitalized
- - - -
-
Pretax Income
5.36B 4.84B 5.63B 6.14B
Pretax Income Growth
-2.77% -9.82% +16.35% +9.03%
Pretax Margin
+17.18% +14.95% +16.78% +16.87%
Income Tax
1.58B 1.13B 936.00M 1.30B
Income Tax - Current - Domestic
- 1.30B 756.00M 583.00M
Income Tax - Current - Foreign
- 530.00M 905.00M 692.00M
Income Tax - Deferred - Domestic
- (336.00M) (435.00M) (322.00M)
Income Tax - Deferred - Foreign
- 83.00M (93.00M) (17.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.78B 3.70B 4.69B 4.84B
Minority Interest Expense
26.00M 28.00M 30.00M 37.00M
Net Income
3.76B 3.68B 4.66B 4.80B
Net Income Growth
-25.44% -2.18% +26.82% +2.96%
Net Margin Growth
+12.03% +11.36% +13.90% +13.20%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.76B 3.68B 4.66B 4.80B
Preferred Dividends
- - - -
-
Net Income Available to Common
3.76B 3.68B 4.66B 4.80B
EPS (Basic)
2.826 2.7687 3.6263 3.7455
EPS (Basic) Growth
-24.71% -2.03% +30.97% +3.29%
Basic Shares Outstanding
1.33B 1.33B 1.29B 1.28B
EPS (Diluted)
2.8196 2.7635 3.6142 3.73
EPS (Diluted) Growth
-24.38% -1.99% +30.78% +3.20%
Diluted Shares Outstanding
1.33B 1.33B 1.29B 1.29B
EBITDA
8.21B 8.38B 9.05B 10.48B
EBITDA Growth
-7.72% +2.08% +8.06% +15.79%
EBITDA Margin
+26.28% +25.89% +27.00% +28.83%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 97.32
Number of Ratings 33 Current Quarters Estimate 1.389
FY Report Date 07 / 2026 Current Year's Estimate 5.967
Last Quarter’s Earnings 1.55 Median PE on CY Estimate N/A
Year Ago Earnings 5.53 Next Fiscal Year Estimate 6.39
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 26 26 30 27
Mean Estimate 1.39 1.35 5.97 6.39
High Estimates 1.41 1.43 6.13 6.63
Low Estimate 1.38 1.32 5.91 6.20
Coefficient of Variance 0.48 2.08 0.86 1.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 17 16
OVERWEIGHT 2 2 5
HOLD 12 14 11
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Medtronic Plc - MDT

Date Name Shares Transaction Value
Apr 30, 2026 Scott C. Donnelly Director 23,679 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 1,939,310.10
Apr 30, 2026 Denise L. Blomquist Chief Accounting Officer 13,580 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Joon Sup Lee Director 1,803 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Gregory P. Lewis Director 5,754 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 471,252.60
Apr 30, 2026 Gregory P. Lewis Director 5,961 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Elizabeth G. Nabel Director 19,584 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 1,603,929.60
Apr 30, 2026 Elizabeth G. Nabel Director 19,791 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 John P. Groetelaars Director 1,444 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Lidia L. Fonseca Director 7,644 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 626,043.60
Apr 30, 2026 Lidia L. Fonseca Director 7,851 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Kevin E. Lofton Director 10,140 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 830,466.00
Apr 30, 2026 Kevin E. Lofton Director 10,347 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Craig Arnold Director 42,185 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 3,454,951.50
Apr 30, 2026 Craig Arnold Director 42,392 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 William R. Jellison Director 6,444 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Randall J. Hogan Director 48,998 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 4,012,936.20
Apr 30, 2026 Randall J. Hogan Director 49,205 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Kendall J. Powell Director 51,380 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $81.9 per share 4,208,022.00
Apr 30, 2026 Kendall J. Powell Director 51,587 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2026 Scott C. Donnelly Director 23,886 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Medtronic Plc in the News